Shopping Cart 0
Cart Subtotal
USD 0

Cipher Pharmaceuticals Inc (CPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to moderate plaque psoriasis of the elbows and knee in adults; epuris, an oral retinoid indicated for the treatment of severe nodular and inflammatory acne; and vaniqa, a topical cream indicated to reduce the growth of unwanted facial hair in women. Its pipeline products under development can be used in the treatment of seborrheic dermatitis, plaque psoriasis, chronic pruritus, rheumatoid arthritis, late stage melanoma, and others. Cipher's pre-clinical compounds are intended for the treatment of melanoma and other cancers. The company provides healthcare professionals with several non-prescription products. Cipher is headquartered in Mississauga, Ontario, Canada.

Cipher Pharmaceuticals Inc (CPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13

Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14

Partnerships 15

Cipher Pharma and Italmex Enter into Distribution Agreement 15

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16

Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17

Licensing Agreements 18

Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 18

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 19

Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 20

Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 21

Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 22

Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 23

BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 24

Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 25

Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 26

Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 27

Debt Offering 28

Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 28

Asset Transactions 29

EPI Health Acquires US Commercial Assets from Cipher Pharma 29

Acquisition 30

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 30

Cipher Pharma Acquires Innocutis 32

Cipher Pharmaceuticals Inc-Key Competitors 33

Cipher Pharmaceuticals Inc-Key Employees 34

Cipher Pharmaceuticals Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

Aug 10, 2018: Cipher Pharmaceuticals reports Q2 2018 results 36

May 10, 2018: Cipher Pharmaceuticals Reports Q1 2018 Results 38

Feb 28, 2018: Cipher Pharmaceuticals Reports Q4 & FY2017 Results 40

Nov 03, 2017: Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results 42

Aug 11, 2017: Cipher Pharmaceuticals reports Q2 2017 financial results 44

Mar 02, 2017: Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results 45

Corporate Communications 46

Apr 12, 2017: Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors 46

Mar 20, 2017: Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13

Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14

Cipher Pharma and Italmex Enter into Distribution Agreement 15

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16

Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17

Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 18

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 19

Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 20

Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 21

Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 22

Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 23

BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 24

Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 25

Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 26

Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 27

Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 28

EPI Health Acquires US Commercial Assets from Cipher Pharma 29

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 30

Cipher Pharma Acquires Innocutis 32

Cipher Pharmaceuticals Inc, Key Competitors 33

Cipher Pharmaceuticals Inc, Key Employees 34

Cipher Pharmaceuticals Inc, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cipher Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to moderate plaque psoriasis of the elbows and knee in adults; epuris, an oral retinoid indicated for the treatment of severe nodular and inflammatory acne; and vaniqa, a topical cream indicated to reduce the growth of unwanted facial hair in women. Its pipeline products under development can be used in the treatment of seborrheic dermatitis, plaque psoriasis, chronic pruritus, rheumatoid arthritis, late stage melanoma, and others. Cipher's pre-clinical compounds are intended for the treatment of melanoma and other cancers. The company provides healthcare professionals with several non-prescription products. Cipher is headquartered in Mississauga, Ontario, Canada.

Cipher Pharmaceuticals Inc (CPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13

Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14

Partnerships 15

Cipher Pharma and Italmex Enter into Distribution Agreement 15

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16

Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17

Licensing Agreements 18

Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 18

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 19

Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 20

Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 21

Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 22

Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 23

BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 24

Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 25

Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 26

Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 27

Debt Offering 28

Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 28

Asset Transactions 29

EPI Health Acquires US Commercial Assets from Cipher Pharma 29

Acquisition 30

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 30

Cipher Pharma Acquires Innocutis 32

Cipher Pharmaceuticals Inc-Key Competitors 33

Cipher Pharmaceuticals Inc-Key Employees 34

Cipher Pharmaceuticals Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

Aug 10, 2018: Cipher Pharmaceuticals reports Q2 2018 results 36

May 10, 2018: Cipher Pharmaceuticals Reports Q1 2018 Results 38

Feb 28, 2018: Cipher Pharmaceuticals Reports Q4 & FY2017 Results 40

Nov 03, 2017: Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results 42

Aug 11, 2017: Cipher Pharmaceuticals reports Q2 2017 financial results 44

Mar 02, 2017: Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results 45

Corporate Communications 46

Apr 12, 2017: Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors 46

Mar 20, 2017: Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cipher Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13

Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14

Cipher Pharma and Italmex Enter into Distribution Agreement 15

Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16

Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17

Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 18

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 19

Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 20

Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 21

Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 22

Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 23

BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 24

Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 25

Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 26

Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 27

Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 28

EPI Health Acquires US Commercial Assets from Cipher Pharma 29

Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 30

Cipher Pharma Acquires Innocutis 32

Cipher Pharmaceuticals Inc, Key Competitors 33

Cipher Pharmaceuticals Inc, Key Employees 34

Cipher Pharmaceuticals Inc, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cipher Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.